Clay Siegall is the President and Co-founder of Seattle Genetics. He also sits as the Chairmen and on the Board of Directors for his biotechnological company. Siegall trained in science and received a doctorate degree which specialized in cancer treatment therapies. As a result of his extensive training and experience on the board of Directors for Alder Biopharmaceuticals, Mirna therapeutics, and Ultragenyx Pharmaceuticals Siegall was able to create Seattle Genetics. The company was built based on a strong foundation in scientific inquiries and research to create treatment drugs that can help cancer patients. He started the company by forming a conglomerate with individuals who held the similar beliefs in cancer therapy approaches.
Seattle genetics is a leader in the biotechnological field for its antibody-drug coagulates (ADCs) including ADCENTRIS, an ADC used worldwide. Siegall has helped Seattle Genetics enter multiple licenses with companies like Pfizer, GlaxoSmithKline, Abbvie, and Genetech (formerly known as Roche). He has earned over $325 million through his innovative programs. After the success of ADCETRIS, Seattle Genetics began planning the formulation of 12 new drugs to treat different types of illnesses. ADCETRIS was specifically formulated to treat systematic large cell lymphoma and Hodgkins lymphoma. In development are also the drugs MMAF to treat non-Hodgkin lymphoma symptoms, ASG-5ME to aid patients with pancreatic, gastric, and prostate cancers, ASG-22E to treat lung, breast, pancreatic, and bladder cancer, and SGN-CD19A to treat hematologic malignancies. Siegall has over 20 clinical trials running to determine the effectiveness of these pipeline drugs and make changes as needed.
Dr. Siegall uses Facebook to interact with the public. He creates posts and finds articles that support his work. He uses social media to not only advertise his company but also to educate followers on cancer and ways it can be treated.